Privately, but he was turned down. Then, he attacked SRPT on his conference call when he compared the two data. This is something never ever happened in the history of Pharmaceuticals business. Just saying!
The European Central Bank president will announce a 550 billion-euro ($640 billion) bond-purchase program this week to make his biggest push yet to steer the euro area away from deflation by announcing quantitative easing on Jan. 22, according to 93 percent of respondents in a Bloomberg News survey. The median estimate of the size of the package tops the 500 billion euros in models presented to officials this month. This may push VJET up slightly tomorrow.
"With greater than three years of eteplirsen experience, the clinical outcomes that our team has demonstrated in the testing of these boys exhibit greater stability in function than anticipated at a time when we often observe a more significant decline without treatment. Based on my many years of caring for patients with this devastating disease, I view these more than 3 years of data as very encouraging," said Jerry Mendell, M.D., director of the Centers for Gene Therapy and Muscular Dystrophy at Nationwide Children’s Hospital and principal investigator of Study 202. "The safety profile of eteplirsen continues to impress me. We have not witnessed any clinically meaningful treatment-related adverse events during the 168 weeks of eteplirsen treatment."
Billy Ellsworth is taking a different exon-skipping drug, eteplirsen, developed by Sarepta Therapeutics. The two drugs are different chemically, and it is possible that eteplirsen may prove more effective.
It seems you have missed the boat. Greed takes you no where. It was low 7's today, but you wanted more under $7. You got what you deserve, and by early next year we will be low to mid 10's. Cheers
Please tell the board doesn't even sound right. I'm long on SRPT, but getting info from someone has nothing to do with the company is kind of silly. Who is she? If she is a mother, then what the board sentiments got to do with anything. Just saying.
Your post clearly indicate that you have missed the low of Friday, and apparently not happy with your move :)
Voxeljet (VJET) recently delivered good results. With an impressive improvement in revenue, Voxeljet is looking well-positioned to deliver a better financial performance in the coming quarters. Management is counting on various initiatives that can act as growth drivers for the company. It is also expecting a positive contribution from Propshop, which it recently acquired. The company is expecting better printer sales on the back of a backlog worth #$%$4.1 million, which will add to its revenue growth. In addition, customer interest in coating activity is still strong, and with growing demand, Voxeljet is expecting a good ramp up in this area.
This transition will benefit Voxeljet
There is a transition going on in the 3D printing industry to shift it from prototyping to being used for production. Voxeljet is aligning itself towards this transition as this will help the company to ramp up capacity at its facility which will also help the company to enter some long term volume contracts with some of the potential contracts, strengthening its long term prospects. Moreover, this has lot to contribute to Voxeljet’s journey.
This all good. But, why do we have to go this route to begin with! Something is wrong with the FDA or Sarepta here. Why would Sarepta need mothers of ailing kids to deliver a message to FDA or Congress. I just don't get it. It seems there is a beef between the FDA and CG. I almost guarantee you if he step down, the medicine will be approved. Anyone?
It was a powerful presentation from a desperate mothers in a dire situation. I'm long on Sarepta, and these mothers agreed that the FDA is wrong on its latest decision. Does Sarepta need these poor mother to make its case and show the world its drug is working? I just don't get it. It seems there is a personal problems between the FDA and CG, but someone needs to get to the bottom of it because kids are dying here and this is the ONLY medicine work so far.
They screwed up big with their approach to SRPT. It is the first time ever the FDA has to explain its action. Tomorrow should be interesting to see the reaction of investors.
As you have noted the article and the clip came around 1:45pm today during a rough day or the market, but VJET held its ground and went up actually. I actually liked what I saw and the potential is huge. I'm long since the 20's level and this company will be a play maker by mid of next year.